Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America

NCT05924789 | Completed

• 1 other identifier: LACOG0222
• Study Type: observational
• Target: 120
• Locations: 2 countries
• Sites: 6

Brief Summary

Currently, there is no Brazilian or Latin American epidemiological data, such as clinical-pathological characteristics, standard treatments and outcomes of gastric cancer and pancreatic cancer in the region. The study aims to create a Latin American multicenter database to analyze epidemiological, clinical, and pathological data, treatments, outcomes, and biological information from patients with gastric and pancreatic cancer.

Conditions

Gastric Cancer; GastroEsophageal Cancer; Pancreatic Cancer

Outcome Measures

Primary Outcomes (1)

• Describe the treatment patterns

  Describe the treatment patterns and outcomes of patients with gastric and gastroesophageal junction cancer in Latin America.

  During study duration (one year)

Study Arms (2)

Cohort A

120 patients with histological diagnosis of gastric and gastroesophageal junction cancer.

Other: Observational study

Cohort B

80 patients histological diagnosis of pancreatic cancer.

Other: Observational study

Interventions

Observational study OTHER

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Cohort A; Cohort B

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with gastric and gastroesophageal junction or pancreatic cancer after January 2019.

You may qualify if:

• ≥18 years
• Histological diagnosis of gastric and gastroesophageal junction cancer (Cohort A) or histological diagnosis of pancreatic cancer (Cohort B);
• Advanced disease diagnosis from January 2019: patients can be included prospectively. Advanced disease is defined as metastatic disease or locally advanced disease not amenable to curative therapy;
• Availability of adequate medical data for data collection.

You may not qualify if:

• Synchronous invasive tumor or second primary tumor in the last three years (except thyroid tumors or non-melanoma skin);
• Nonepithelial histology in Cohort A: Sarcoma, GIST, lymphoma, and tumors of neuroendocrine origin;
• Nonepithelial histology in Cohort B: Sarcoma, GIST, lymphoma, pancreatoblastoma, and tumors of neuroendocrine origin.

Sponsors & Collaborators

• Latin American Cooperative Oncology Group: lead
• Astellas Pharma Inc: collaborator
• Grupo Argentino de Investigación Clínica en Oncología (GAICO): collaborator

Study Sites (6)

Instituto de Oncología San Gerónimo

Santa Fe, Santa Fe Province, Argentina

Location

ÉTICA Clínica AMO - Assistência Multidisciplinar em Oncologia

Salvador, Estado de Bahia, 41.950-640, Brazil

Location

HMV - Hospital Moinhos de Vento

Porto Alegre, Rio Grande do Sul, 90.035-000, Brazil

Location

CEPON - Centro de Pesquisas Oncológicas

Florianópolis, Santa Catarina, 88.034-000, Brazil

Location

BP - A Beneficência Portuguesa de São Paulo

São Paulo, 01.323-030, Brazil

Location

A.C. Camargo Cancer Center

São Paulo, 01.509-001, Brazil

Location

MeSH Terms

Conditions

Stomach Neoplasms; Pancreatic Neoplasms

Interventions

Observation

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Study Officials

• Renata D´Alpino Peixoto

  Latin American Cooperative Oncology Group

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 8, 2023
• First Posted: June 29, 2023
• Study Start: August 11, 2023
• Primary Completion: September 24, 2024
• Study Completion: September 24, 2024
• Last Updated: February 12, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

AR (1); BR (5)